This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Hercules, CA, Bio-Rad Laboratories is a manufacturer and global supplier of clinical diagnostics and life science research products in the healthcare, analytical chemistry life science research and other markets. It offers a wide portfolio of products and systems which allow the separation of complex chemical and biological materials and discovery, analysis and purification of their components. Bio-Rad has extensive and direct distribution channels in over 35 countries outside the United States through subsidiaries which focus on sales, customer service and product distribution.
QIAGEN Q4 Earnings Miss, Stock Crashes, Margins Expand
by Zacks Equity Research
QGEN's performance benefits from a resilient portfolio in the fourth quarter of 2024.
PAHC Stock Falls Despite Q2 Earnings & Revenue Beat, Margins Increase
by Zacks Equity Research
Phibro's second-quarter fiscal 2025 results reflect the strong performance of the legacy Animal Health business.
Earnings Preview: Bio-Rad Laboratories (BIO) Q4 Earnings Expected to Decline
by Zacks Equity Research
Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Labcorp Q4 Earnings & Revenues Beat, Margins Down, Stock Tumbles
by Zacks Equity Research
LH delivers better-than-expected revenues and earnings in the fourth quarter of 2024.
Hologic Q1 Earnings Beat, Stock Falls on Dismal '25 Sales Guidance
by Zacks Equity Research
HOLX's fiscal 2025 first-quarter results reflect the strength of its Molecular Diagnostics business.
BSX Q4 Earnings & Revenues Top, Stock Falls on Weak Gross Margin
by Zacks Equity Research
Boston Scientific's fourth-quarter 2024 performance reflects the strength of its core franchises.
Has BioRad Laboratories (BIO) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Bio-Rad Laboratories (BIO) and Certara, Inc. (CERT) have performed compared to their sector so far this year.
Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Adaptive Biotechnologies (ADPT) and Bio-Rad Laboratories (BIO) have performed compared to their sector so far this year.
Why Bio-Rad Stock is an Apt Pick for Your Portfolio Right Now
by Zacks Equity Research
BIO's robust performance of the ddPCR platform and clinical diagnostics momentum bodes well for investors.
Bio-Rad (BIO) Down 5.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Bio-Rad (BIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Interpreting Bio-Rad (BIO) International Revenue Trends
by Zacks Equity Research
Examine the evolution of Bio-Rad's (BIO) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
BIO Q3 Earnings and Revenues Surpass Estimates, Stock Up Aftermarket
by Zacks Equity Research
Bio-Rad witnesses growth across the Clinical Diagnostics segment in the third quarter, primarily driven by an increased demand for quality control and immunology products.
Bio-Rad Laboratories (BIO) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Bio-Rad (BIO) delivered earnings and revenue surprises of 57.03% and 2.02%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
What to Expect From These 3 MedTech Stocks This Earnings Season
by Urmimala Biswas
Here is a sneak peek into how three MedTech companies, ZBH, BIO and TECH, are expected to fare in their upcoming quarterly results, slated to be released tomorrow.
Analysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FitLife Brands (FTLF) Soars 5.7%: Is Further Upside Left in the Stock?
by Zacks Equity Research
FitLife Brands (FTLF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
BIO Gears Up for Q3 Earnings: Here's What You Need to Know
by Zacks Equity Research
Within Bio-Rad's Life Science business, the ongoing weakness in the biotech and biopharma end markets might have severely affected sales.
Should You Continue to Hold Bio-Rad Stock in Your Portfolio?
by Zacks Equity Research
BIO strategically expands its ddPCR platform while eyeing global expansion and benefiting from its clinical diagnostics arm.
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RSPH)?
by Zacks Equity Research
Sector ETF report for RSPH
National Vision (EYE) Down 6.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
National Vision (EYE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Reasons to Retain Bio-Rad (BIO) Stock in Your Portfolio Now
by Zacks Equity Research
Bio-Rad's (BIO) robust digital PCR business and Clinical Diagnostics segments raise optimism. However, macro issues raise concerns.
Bio-Rad (BIO) Faces Low BioPharma Demand, Competitive Pressure
by Zacks Equity Research
Bio-Rad (BIO) is experiencing weaker sales in Asia as China is currently entangled in a challenging research funding environment, and Japan, too, is facing constrained funding issues.
Bio-Rad (BIO) Q2 Earnings Surpass Estimates, Guidance Lowered
by Zacks Equity Research
Bio-Rad (BIO) witnesses growth in the second quarter across the Clinical Diagnostics segment, primarily driven by an increased demand for quality control and blood typing products.
Bio-Rad Laboratories (BIO) Surpasses Q2 Earnings Estimates
by Zacks Equity Research
Bio-Rad (BIO) delivered earnings and revenue surprises of 46.70% and 1.55%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for These 4 MedTech Stocks in Q2 Earnings?
by Urmimala Biswas
Here is a sneak peek into how four MedTech companies, LH, BIO, TFX and BRKR, are expected to fare in their second-quarter results, slated to be released tomorrow.